Johnson & Johnson (JNJ) is one of the largest healthcare companies in the world. It employs over 120,000 people in its two divisions, Pharmaceutical and MedTech. It spun off its consumer healthcare division in 2023, naming it Kenvue. About 64% of its $88.8 billion in 2024 revenues came from its pharmaceutical division, while the remaining 36% was from its MedTech operations.
Since our last review in April 2025, J&J has gained roughly 70% and touched an all-time high of $269. The stock is up 27% this year alone. That’s extraordinary for a name we own as ballast.
Wealth Builder
Sorry!
Only current subscribers of the Internet Wealth Builder may view the details of this recommendation.